Incyte Drug Jakafi to Treat Polycythemia Vera (PV)

December 6, 2014 1:51 PM

3 0

The Food and Drug Administration (FDA) has approved Incyte drug Jakafi to treat Polycythemia Vera in patients who have had an unsatisfactory response to or do not tolerate hydroxyurea. This is the first time the FDA has approved a drug for PV.

Jakafi, a targeted kinase inhibitor manufactured by Incyte, reportedly offers a salutary option for some people affected by this serious blood disorder, a type of myeloproliferative disease.

Read more

To category page